Phaseline

Targets › NDNF

NDNF (Protein NDNF): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Mar 2028.

Secretory protein that plays a role in various cellular processes. Acts as a chemorepellent acting on gonadotropin-releasing hormone (GnRH) expressing neurons regulating their migration to the hypothalamus. (UniProt, Q8TB73)

Open in Phaseline: the race on NDNF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ruijin HospitalNTF001 Injection
AAV-mediated gene therapy expressing human neuron-derived neurotrophic factor (NDNF)
NDNFPhase 1ALS - Amyotrophic Lateral SclerosisMar 2028

Conditions

ALS - Amyotrophic Lateral Sclerosis (1)

Modalities

other (1)

Companies

Ruijin Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.